Interface Biologics
ClosedToronto, Canada · Founded 2001 · $8.0M raised
- Headquarters
- Toronto
- Founded
- 2001
- Business Model
- B2B
- Total Funding
- $8.0M
- Last Round
- $1.0M Series BJan 2015
- Rounds
- 4
About
Interface Biologics is a Toronto-based biomaterials company, founded in 2001, that developed proprietary, nano-engineered surface-modification polymer technologies to improve the safety and performance of medical devices, including its Endexo platform used to reduce clot risk on implants. In 2019 the company sold its surface-modification business to Evonik, and its team went on to found the ophthalmic drug-delivery spinout Ripple Therapeutics in 2020.
Summary
Interface Biologics is a Healthcare company based in Toronto, Canada, founded in 2001. It has raised $8.0M in total across 4 rounds, most recently a $1.0M Series B round in Jan 2015. Investors include BDC Venture Capital, DSM Venturing and MaRS Investment Accelerator Fund.
Funding History
Jan 2015
Sign up to see all 4 rounds
Venture Round through Series B — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/interface-biologics"><img src="https://indexed.vc/api/badge/company/interface-biologics" alt="Interface Biologics on Indexed.vc" width="260" height="76" /></a>